Eli Lilly & Co. vs. Royalty Pharma plc Class A Ordinary Shares
LLY
Eli Lilly & Co.
$1209.00 -0.92%
VS RPRXRoyalty Pharma plc Class A Ordinary Shares
$58.60 +0.07%
Eli Lilly & Co. and Royalty Pharma plc Class A Ordinary Shares are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| LLY | RPRX | |
|---|---|---|
| Market Cap | $1.09 trillion | $26.37 billion |
| Revenue (TTM) | — | $2.54 billion |
| Net Income (TTM) | — | $1.35 billion |
LLY leads on 1 of 1 size & scale factors.
Valuation
| LLY | RPRX | |
|---|---|---|
| P/E Ratio | — | 31.17 |
| Price / Book | — | 2.69 |
| Price / Sales | — | 10.40 |
LLY and RPRX split the valuation factors evenly.
Profitability
| LLY | RPRX | |
|---|---|---|
| Net Margin | — | 53.23% |
| Return on Equity | — | 13.79% |
LLY and RPRX split the profitability factors evenly.
Dividend
| LLY | RPRX | |
|---|---|---|
| Dividend Yield | — | 1.60% |
| Payout Ratio | — | 50.00 |
LLY and RPRX split the dividend factors evenly.
Risk & Sentiment
| LLY | RPRX | |
|---|---|---|
| Short Interest | 1.29% | 0.34% |
RPRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, RPRX overview, RPRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.